J&J Remediates Two OTC Facilities To FDA Approval, Waits On Third

08 Jun 2015

Its headquarters plant was closed and production at two other facilities was slowed under a 2011 consent decree. J&J did not say when it expects FDA’s decision on the third plant.

Two McNeil Consumer Healthcare manufacturing plants are cleared to resume full production as FDA considers signing off on remediation of the Johnson & Johnson subsidiary’s closed headquarters facility.

In a statement to “The Tan Sheet,” J&J on June 4 said FDA officials signed off on remediation required under...